

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, May 12, 2014 – Astellas Pharma Inc. (Tokyo : 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.
2. Contents of acquisition
 - (1) Class of shares to be acquired: Common stock of the Company
 - (2) Total number of shares to be acquired: Up to 24 million shares
(The percentage compared to the total number of shares outstanding: 1.08%)
 - (3) Aggregate amount of acquisition cost: Up to 30 billion yen
 - (4) Period of acquisition: From May 13, 2014 to June 23, 2014

(Reference)

The status of treasury shares as of March 31, 2014:

Total number of shares outstanding:	446,228,356 shares
Number of treasury shares:	10,736,279 shares

The Company conducted a stock split, effective April 1, 2014, as announced in its press release dated February 28, 2014, “Astellas Announces Stock Split and Partial Amendment to the Articles of Incorporation”. If the above shares as of March 31, 2014 were converted in accordance with the stock split, the number of share would be as follows.

Total number of shares outstanding:	2,231,141,780 shares
Number of treasury shares:	53,681,395 shares

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en